Li Yunxiao, Hind Charlotte, Furner-Pardoe Jessica, Sutton J Mark, Rahman Khondaker Miraz
School of Cancer and Pharmaceutical Science, King's College London, London SE1 9NH, UK.
Antimicrobial Discovery Development and Diagnostics Team, UK Health Security Agency, Porton Down SP4 0JG, UK.
JAC Antimicrob Resist. 2025 Jun 23;7(3):dlaf106. doi: 10.1093/jacamr/dlaf106. eCollection 2025 Jun.
Cases of infection have been on the rise in recent years. A comprehensive and clear understanding of the mechanisms of antifungal resistance is fundamental for developing novel therapies to address the current and emerging threat of fungal diseases. Certain species can cause superficial or invasive infections in immunocompromised hosts, and invasive infections are major contributors to infectious disease deaths. As fungi are eukaryotes like humans, there are only a limited number of unique molecular targets available for antifungal drug development. Until recently, there have only been four primary classes of antifungals used to treat systemic fungal infections. Among these, azole antifungals are globally used because they are both inexpensive and effective. Due to various factors, resistance to antifungal drugs-especially azole antifungals-has developed in many species, posing a significant public health threat. This review discusses the known mechanisms of azole antifungal resistance in , , , , and explores strategies to overcome the resistance problem.
近年来,感染病例一直在增加。全面、清晰地了解抗真菌耐药机制是开发新疗法以应对当前和新出现的真菌疾病威胁的基础。某些物种可在免疫功能低下的宿主中引起浅表或侵袭性感染,侵袭性感染是传染病死亡的主要原因。由于真菌是像人类一样的真核生物,用于抗真菌药物开发的独特分子靶点数量有限。直到最近,用于治疗全身性真菌感染的抗真菌药物主要只有四类。其中,唑类抗真菌药物在全球范围内被使用,因为它们既便宜又有效。由于各种因素,许多物种对抗真菌药物,尤其是唑类抗真菌药物产生了耐药性,对公共卫生构成了重大威胁。本综述讨论了在[具体物种1]、[具体物种2]、[具体物种3]、[具体物种4]、[具体物种5]中唑类抗真菌耐药的已知机制,并探讨了克服耐药问题的策略。